Source: Shutterstock
Everlit Audio Player
Subscribe today to listen to this content Get Access

Phase 3 enrollment of 417 patients for the landmark MODEL trial of a novel peptide intradiscal injection for low back pain is now completed.

Study sponsor, Spine BioPharma, Inc., made this announcement at the recently concluded 2024 North American Spine Society annual meeting.

Subscribe to continue reading

Register to read 3 free articles
  • Unlimited access to our content and archive
  • Exclusive access to our newsletter
  • Join the Conversation! Exclusive access to article comments.
Sign in to an existing account